This Bottom Bouncer Looks Primed To Pick Up More Traction Print E-mail
By M.E.Garza   

This low float biotech stock which has several catalysts on tap appears ready to head higher after a very recent trend reversal.

We haven't covered TapImmune, Inc.(OTCQB: TPIV) since it first caught our eye when it was trading as a pure penny play, but the firm has now developed a strong pipeline and it catches our attention as an undervalued reversal play.

The recent valuation of IPO biotechs like Kite Pharma, Inc. (NASDAQ:KITE) whose immunotherapy T-Cell technology pipeline is only slightly ahead of Tapimmune's own pipleline of technologies, trades at a stunning $1.07 Billion market cap is an indicator that this particular immunotherapy space may be heating up again.

After attending some recent biotech conferences, we are hearing some very positive buzz about TapImmune, Inc.-- still a relatively small cap biotech company which is specializing in the development of innovative immunotherapeutic vaccines in a couple of billion dollar areas in oncology and infectious disease. SeeThru Equity recently called for a $7 price target for this stock, which currently only trades with a $31M market cap. The Seattle Washington based firm has a strong pipeline and numerous milestone announcements expected, but perhaps most interstingly, they've been able to bring a couple of new T cell stimulation peptide based vaccines for the treatment of cancer without spending too much money. In addition, they recently eliminated most of their debt by doing a re-structuring as part of what management calls "a very successful cleanup effort."   

The company’s lead pipeline candidate, TPIV100, represents a potentially significant advancement from current therapies. In fact, TPIV's vaccines address a significant unmet market need. They are applicable to a much larger and broader patient population than current ‘standard of care’ therapies like Herceptin by Roche which is useful for only 15-20% of the Her2neu Breast Cancer patient population. Herceptin is not designed to kill tumor cells (it slows tumor growth). 2013 Herceptin sales exceeded $6 Billion. TPIV vaccine is applicable to over 50% of the Her2neu patient population AND is also not limited to breast cancer. Her2neu is a target for TPIV in both Colorectal and Ovarian cancer where there are very few therapeutic options.

In addition, we really like TPIV's unique vaccine platform Antigen Expression Systems called PolyStart that ‘boosts’ the presentation of the desired peptide on the surface of the cell for the Killer T Cells to recognize and kill. This totally novel system creates a 4 (FOUR) fold increase in antigen presentation and
in current studies in smallpox has shown to be working very well. Nobody has this technology and

Error. Page cannot be displayed. Please contact your service provider for more details. (24)

it has unlimited application in oncology and infectious diseases not only in our own platforms but can be applied to many others via licensing. Ideal candidates for this type of technology include Provenge, Yervoy and
many more.

As pointed out in the recent analysis of the company, unlike other vaccine technologies that narrowly address the initiation of animmune response, TapImmune's ("Prime" and "Boost") approach utilizes aproprietary set of peptide antigens to broadly stimulate the cellular immunesystem. TapImmune’s platform technologies restore protein expressionwithin cancerous cells, making them immunogenic and providing a signal tothe immune system to attack the cancer. This unique approach will allowTapImmune to treat wider patient populations than currently utilizedtherapies, treat patients across multiple indications and treat multipletherapeutic areas. TapImmune is also exploiting the emerging field ofvaccinomics for the development of vaccines applicable to a broad patientpopulation. Vaccines have been a significant driver of value forpharmaceutical companies in recent years, and cancer vaccines inparticular are at the forefront of a new wave of cancer treatments.TapImmune believes it has the most comprehensive T-Cellimmunotherapeutic vaccines in development, which have the potential tocapitalize on these attractive industry dynamics.

 

Beautiful Bottom Bounce Play Chart:

We like the technical analysis chart here too, but particularly if the stock manages to break the $2 mark in the next session or so. If it manages to, then we could see a run to $2.50 where it should meet additional resistance, then $3 if it breaks past that mark. Because there are not that many shares in the float, you'll notice that the stock has ran as high as $7.00 on positive Phase I data news.


Catalysts

One of the key goals driving the company is a move on to the NASDAQ exchange. "I think it helps us in many ways, including the prestige and the type of investor pool we will have access to." said Glynn Wilson, CEO of TapImmune.
TapImmune is focused on developing four product candidates, two of which are currently finishing phase I studies at the Mayo Clinic in Rochester, MN.
The company plans to commence phase Ib/II studies in 4Q14E on its HER2/neu breast cancer andfolate alpha breast/late stage ovarian cancer programs.
The other two product candidates, Polystart™ and TAP, areproprietary immunotherapeutic technologies that are in preclinical trials. Wewould expect to receive significant milestone updates from TapImmuneover the next 6-12 months to act as catalysts for the shares.

Disclosure: Long TPIV since 2012




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 
BMR:1